Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Vehicle cream: same formulation of cream as the test product but without active substance and phosphoric acid, Ruxolitinib (INCB018424) cream
Incyte
Atopic Dermatitis
1 trial -
Veltassa 8.4 g powder for oral suspension, Placebo
Istituto Gentili S.r.l.
End Stage Kidney Disease on chronic dialysis therapy
1 trial -
Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
1 trial -
Venetoclax
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML
2 trials -
Venetoclax
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Venetoclax
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Lymphoblastic Leukemia
1 trial -
Venetoclax in combination with fludarabine and melphalan
The First People's Hospital of Lianyungang
Venentoclax
1 trial -
Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use
AbbVie Deutschland GmbH & Co. KG
Higher-Risk Myelodysplastic Syndrome
1 trial -
Ventoclax
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML (Acute Myelogenous Leukemia)
1 trial -
Ventolin 100 microgramos/inhalación suspensión para inhalación en envase a presión* (*) sin CFC
GlaxoSmithKline
Asthma
1 trial -
Venues-P Valve
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pulmonary Regurgitation
1 trial -
Verum acupuncture
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet
The George Institute
Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.
The George Institute
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib
Astellas Pharma GmbH
Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets
The George Institute
Acute Myeloid Leukemia, ONCOLOGY
1 trial -
Vincristine Sulfate Liposome
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Adult Acute Lymphoblastic Leukemia
1 trial -
Visilizumab
The First People's Hospital of Lianyungang
Immunotherapy
1 trial -
Vitamin D3
Hospital Authority, Hong Kong
Lupus Erythematosus, Systemic
1 trial -
Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection
ViiV Healthcare Pty Ltd
HIV Infections
1 trial -
Voclosporin
Aurinia Pharmaceuticals
Lupus Nephritis
3 trials -
Voclosporin
Aurinia Pharmaceuticals
Adolescent Lupus Nephritis
2 trials -
Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo
Astellas Pharma GmbH
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma
1 trial -
Warfarin Sodium
Hospital Authority, Hong Kong
Indications for Warfarin Therapy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources